Study To Evaluate The Efficacy And Safety Of A Nutritional Supplement Based On Bergamot, Artichoke And Other Ingredients For Reducing Cholesterol Levels In Patients With Hypercholesterolemia (Metachol+)

Not Applicable

Recruiting

• Conditions: Cholesterolemia

• Registration Number: NCT07178769
• Lead Sponsor: Laboratoires Arkopharma

Brief Summary

The goal of this clinical trial with food supplement is to evaluate the effectiveness of a nutritional supplement based on bergamot, artichoke and other ingredients through low-density lipoprotein (LDL) values after four months of treatment compared to maintaining healthy lifestyle habits.

The secondary objectives are

* Evaluate the improvement of the lipid profile compared to maintaining healthy lifestyle habits.

* Evaluate the difference in effect between 1 tablet and 2 tablets daily in improving the lipid profile.

* Evaluate changes in anthropometric data and vital signs.

* Evaluate adherence to treatment

* Evaluate the safety profile of the product

* Evaluate satisfaction with treatment

There are three treatment arms:

1. Arm 1 (Gr 1): Patients being treated with a nutritional supplement based on bergamot, artichoke and other ingredients with one capsule every night at dinner with a glass of water for four months.

2. Arm 2 (Gr 2): Patients treated with a nutritional supplement based on bergamot, artichoke and other ingredients with two capsules every night at dinner with a glass of water for four months.

3. Arm 3 (Control): Patients not taking METACHOL+. All patients in the study will be recommended to lead an active life and a healthy diet, providing them with instructions to follow according to their usual clinical practice.

It is expected to recruit 207 patients in total, 69 in each group/arm

Detailed Description

Not available

Study Timeline

• Study Start: 2025-04-20
• Status Verified: 2025-06
• Study First Submitted: 2025-09-11
• Study First Submitted QC: 2025-09-11
• Last Update Submitted: 2025-09-11
• Study First Posted: 2025-09-17
• Last Update Posted: 2025-09-17
• Primary Completion: 2026-07-30
• Study Completion: 2026-07-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 207

Inclusion Criteria

1. Patients who are willing and able to understand and sign the informed consent after the nature of the study has been fully explained to them and they have passed the inclusion/exclusion criteria.
2. Patients aged greater than or equal to 18 years
3. Patients with moderate or mild cardiovascular risk, who have LDL levels greater than 130 mg/dl.

Exclusion Criteria

1. Use of any other drug or food supplement for the treatment of hypercholesterolemia during the 30 days prior to selection.
2. Allergy or hypersensitivity to any of the components of the study treatment.
3. Decompensated cardiovascular disease, decompensated diabetes mellitus, decompensated HTN.
4. Serious medical conditions such as: cancer, serious chronic illness considered incompatible with participation in the study or others that may interfere with the study.
5. HIV-AIDS, Pregnancy or breastfeeding, occlusion of the central retinal artery (of foreseeable vascular origin), history of cardiovascular disease and familial hypercholesterolemia.
6. Liver, kidney or muscle disorders.
7. Psychiatric disorders or inability to sign the consent.
8. Subjects with extreme eating habits and/or with a significant history of anorexia nervosa, bulimia and other eating disorders.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Difference in the change in LDL cholesterol after four months of treatment compared to the baseline visit between patients treated	four months	Difference in the change in LDL cholesterol after four months of treatment compared to the baseline visit between patients treated with a nutritional supplement (regardless of its dose) and patients in the control group.; Difference in the change in LDL cholesterol after four months of treatment compared to the baseline visit between patients in group 1, group 2 and patients in the control group.
Difference in the change in LDL cholesterol after fou months of treatment compared to the baseline visit between patients treated in 1, 2 and control group	four months	Difference in the change in LDL cholesterol after four months of treatment compared to the baseline visit between patients in group 1, group 2 and patients in the control group

Secondary Outcome Measures

Name	Time	Method
change in triglycerides	2-4 months	Difference in the change in triglycerides after 2 and 4 months of treatment compared to the baseline visit between patients in group 1 and patients in group 2.
change in VLDL	2-4 months	Difference in the change in VLDL after 2 and 4 months of treatment compared to the baseline visit between patients in group 1 and patients in group 2
change in Apo A	2-4 months	Difference in the change in Apo A after 2 and 4 months of treatment compared to the baseline visit between patients in group 1 and patients in group 2.
change in Apo B	2-4 months	Difference in the change in Apo B after 2 and 4 months of treatment compared to the baseline visit between patients in group 1 and patients in group 2
change in Liposcale	2-4 months	Difference in the change in Liposcale after 2 and 4 months of treatment compared to the baseline visit between patients in group 1 and patients in group 2

Trial Locations

Locations (6)

Centro de Salud Goya; 🇪🇸 Madrid, Madrid, Spain

Centro de Salud Daroca; 🇪🇸 Madrid, Madrid, Spain

Centro de Salud Avenida de Aragón; 🇪🇸 Madrid, Madrid, Spain

Centro de Salud Casco Antiguo; 🇪🇸 Cartagena, Murcia, Spain

Centro de Salud Isaac Peral; 🇪🇸 Cartagena, Murcia, Spain

Centro de Salud de Mazarrón; 🇪🇸 Mazarrón, Murcia, Spain